consecut
bal
sampl
obtain
hsct
recipi
fred
hutchinson
cancer
research
center
fhcrc
seattl
acut
pulmonari
infiltr
one
respiratori
viru
season
use
studi
initi
evalu
sampl
includ
routin
viral
bacteri
fungal
mycobacteri
cultur
shellvial
cultur
cytomegaloviru
cmv
respiratori
syncyti
viru
rsv
direct
fluoresc
antibodi
stain
herpesvirus
respiratori
virus
legionella
speci
cytolog
test
use
method
discuss
elsewher
brief
bal
sampl
inocul
human
foreskin
fibroblast
hff
rhesu
monkey
kidney
rmk
cell
cultur
maintain
rmk
day
hff
shellvial
centrifug
cultur
perform
use
cmv
rsvspecif
antibodi
accord
standard
techniqu
describ
elsewher
bacteri
fungal
mycobacteri
cultur
use
standard
methodolog
clinic
microbiolog
laboratori
fhcrc
direct
fluoresc
antibodi
stain
perform
cmv
adenoviru
parainfluenza
virus
influenza
virus
b
rsv
legionella
speci
use
pathogenspecif
monoclon
antibodi
bartel
accord
manufactur
instruct
aliquot
bal
sampl
kept
frozen
subsequ
test
blind
condit
univers
virginia
hrv
human
coronaviru
use
rtpcr
techniqu
describ
elsewher
human
coronaviru
rtpcr
done
first
sampl
detect
amplif
product
done
micropl
hybrid
accord
publish
method
minor
modif
patient
characterist
treatment
record
obtain
electron
databas
patient
chart
maintain
fhcrc
seventyseven
patient
newli
diagnos
pulmonari
infiltr
chest
radiograph
underw
bronchoscopi
bal
total
sampl
studi
period
tabl
human
coronaviru
rna
detect
sampl
test
six
patient
hrv
rna
detect
bal
sampl
none
patient
cultur
posit
hrv
although
cultur
method
optim
grow
hrv
two
patient
sampl
posit
hrv
bal
sampl
collect
day
apart
respect
one
patient
tabl
first
diagnos
idiopath
pneumonia
syndrom
biopsi
bal
improv
steroid
therapi
patient
develop
lingual
lobe
infiltr
prompt
second
bal
patient
tabl
persist
pulmonari
nodul
improv
treatment
rsv
second
bal
reveal
aspergillu
nidulan
addit
hrv
patient
complain
upper
respiratori
symptom
prior
onset
respiratori
distress
patient
develop
expiratori
wheez
concomit
identif
rsv
bal
fluid
among
posit
hrv
rna
onset
acut
pulmonari
infiltr
averag
day
transplant
rang
day
onset
hrv
infect
occur
first
day
hrvposit
patient
patient
recipi
allogen
hsct
unrel
mismatch
donor
matchedrel
fifti
percent
chronic
graftversushost
diseas
time
ill
onset
none
hrvposit
bal
specimen
grew
hrv
routin
cell
cultur
none
patient
rhinoviru
detect
cultur
upper
respiratori
secret
patient
copathogen
detect
along
hrv
bal
sampl
tabl
patient
initi
bal
specimen
grew
hrv
subsequ
bal
day
later
grew
hrv
aspergillu
niger
frequent
copathogen
aspergillu
speci
patient
parainfluenza
viru
patient
rsv
patient
one
patient
coinfect
cmv
pseudomona
aeruginosa
staphylococcu
aureu
streptococcu
pneumonia
death
occur
patient
patient
die
within
month
onset
respiratori
ill
patient
die
within
month
onset
ill
mean
time
ill
onset
death
day
median
day
rang
day
autopsi
data
avail
fatal
case
relaps
underli
diseas
diagnos
patient
die
find
indic
detect
hrv
bal
fluid
hsct
recipi
pneumonia
associ
high
mortal
rate
frequent
coinfect
suggest
hrv
could
caus
lower
respiratori
tract
diseas
highli
immunosuppress
hsct
recipi
addit
present
studi
demonstr
import
use
sensit
avail
techniqu
diagnos
hrv
patient
popul
cell
cultur
result
may
insensit
unless
specif
effort
taken
isol
rhinovirus
respiratori
virus
increasingli
recogn
associ
sever
respiratori
complic
immunosuppress
hsct
recipi
present
studi
provid
addit
evid
hrv
associ
lifethreaten
lower
respiratori
tract
diseas
patient
hrv
rna
detect
patient
bronchoscopi
bal
acut
pulmonari
infiltr
half
hrvposit
patient
die
first
month
infect
ultim
die
howev
patient
hrv
coinfect
least
pathogen
likewis
associ
increas
mortal
popul
unclear
avail
inform
agent
hrv
copathogen
primari
caus
death
patient
also
clear
data
whether
rhinoviru
caus
lower
respiratori
tract
diseas
interest
patient
identifi
appear
show
persist
hrv
infect
patient
may
morecompromis
immun
predispos
polymicrobi
infect
higher
risk
infecti
mortal
frequenc
coinfect
suggest
hrv
may
predispos
patient
addit
infect
possibl
immunomodulatori
mechan
demonstr
rsv
parainfluenza
viru
indic
vitro
hrv
data
need
confirm
hypothesi
found
patient
present
hrv
infect
first
day
transplant
consist
commun
acquisit
infect
contrast
ghosh
et
al
report
patient
present
infect
within
first
day
transplant
indic
nosocomi
acquisit
strict
infectioncontrol
screen
symptomat
patient
institut
earli
isol
cohort
univers
use
glove
mask
contact
symptomat
patient
strict
implement
hand
wash
restrict
staff
visitor
upper
respiratori
symptom
children
age
year
visit
place
past
year
fhcrc
may
contribut
reduc
risk
nosocomi
hrv
infect
particularli
earli
transplant
addit
studi
took
place
institut
polici
prohibit
staff
uncontrol
respiratori
secret
patient
contact
could
limit
spread
hrv
coronaviru
also
possibl
earlier
symptom
restrict
urt
may
miss
studi
howev
suggest
rapid
progress
lower
airway
involv
occur
result
unlik
patient
infect
long
period
prior
bal
futur
studi
prospect
viral
cultur
upper
airway
get
better
sens
epidemiolog
respiratori
virus
popul
sever
limit
present
studi
conduct
singl
season
singl
center
thu
may
repres
hrv
infect
differ
area
countri
differ
virus
may
circul
studi
period
sampl
detect
patient
concurr
diagnos
pneumonia
chest
radiograph
result
studi
focus
patient
sever
diseas
provid
data
overal
incid
hrv
infect
hsct
recipi
select
patient
pneumonia
probabl
overestim
risk
mortal
secondari
hrv
infect
give
indic
frequenc
progress
upper
airway
diseas
lower
airway
diseas
prior
report
bowden
hsct
recipi
suggest
risk
low
possibl
hrv
may
introduc
lower
respiratori
tract
bronchoscopi
procedur
patient
urt
infect
unfortun
could
test
possibl
pcr
upper
respiratori
sampl
save
context
earlier
studi
perform
mainli
cmv
may
instruct
studi
demonstr
patient
document
cmv
shed
throat
often
neg
bal
cmv
thu
viral
shed
throat
necessarili
associ
lower
respiratori
tract
contamin
viru
optim
bronchoscopi
techniqu
use
intervent
studi
also
need
identifi
optim
way
mang
infect
capsidbind
pleconaril
proteas
ruprintrivir
hrv
inhibitor
current
investig
treatment
prevent
hrv
infect
immunocompet
patient
agent
could
test
see
whether
favor
affect
clinic
cours
complic
hrv
infect
hsct
recipi
pleconaril
current
avail
via
compassionateus
program
manag
hrv
immunocompromis
host
one
report
bone
marrow
transplant
recipi
possibl
rhinoviru
pneumonia
success
treat
pleconaril
part
program
conclus
present
studi
suggest
hrv
infect
may
sometim
associ
sever
lower
respiratori
tract
diseas
pneumonia
hsct
recipi
studi
need
determin
whether
hrv
caus
lytic
infect
act
primarili
via
indirect
immunosuppress
effect
result
increas
predisposit
superinfect
addit
studi
need
better
clarifi
epidemiolog
hrv
infect
hsct
recipi
better
understand
risk
factor
progress
hrv
urt
infect
lower
respiratori
tract
prospect
surveil
studi
hsct
recipi
upper
lower
respiratori
symptom
urt
possibl
lower
respiratori
tract
sampl
collect
assess
presenc
hrv
human
coronaviru
pcr
would
need
delin
true
epidemiolog
respiratori
viral
diseas
popul
prospect
studi
ongo
